Recap: Curis Q2 Earnings

Shares of Curis CRIS were flat in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 29.41% year over year to ($0.12), which missed the estimate of ($0.11).

Revenue of $2,286,000 decreased by 3.14% year over year, which missed the estimate of $2,480,000.

Guidance

Curis hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 03, 2021

Time: 04:30 PM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1827/42178

Recent Stock Performance

52-week high: $17.40

Company's 52-week low was at $0.90

Price action over last quarter: down 46.82%

Company Description

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!